MabVax Therapeutics Holdings Inc

MabVax Therapeutics — Investor Presentation (May 2015)

24 slides from MabVax Therapeutics's investor presentation, May 27, 2015

  1. Slide 1: MabVax Therapeutics Corporate Presentation

    Mi MabVax therapeutics OTCQB: MBVX Corporate Presentation

  2. Slide 2: Disclaimer: Forward Looking Statements

    Disclaimer Forward Looking Statements ‘This presentation contai s forward-looking statements and projections. The company makes no this information ot, in the f the project is i its own independent investigation. il is, her, or Tt must be recognized that estimates of the company actual results. In p

  3. Slide 3: Investment Highlights

    Investment Highlights aa cology secinolnes Substantial ‘Near-Term Clinical Pipeline Efficient Productive Well Managed Mivenvex Capital efficient development model company experience

  4. Slide 4: Management Team and Board of Directors

    Management Team and Board of Directors J:David Hansen Founder, President Board Member Mab Brace De Shang Plough, Key BM Philip Livingston, MD. Founder & Chief Science Officer Gregory Hanson Chief Financial Officer Wolfgang Scholz, PhD. Found & Vie President Antibody Discovery Paul Maffuid, Ph.D. Vie

  5. Slide 5: Capital Efficient Business Model

    Capital Efficient Business Model less intensive Mivenvex 5

  6. Slide 6: Robust Pipeline with Multiple Near-Term Milestones

    Robust Pipeline with Multiple Near-Term Milestones PreIND | Phase | Phase? | Phase} NNSKCG Patheon NILASKC, | Patheon Metasttie Pancreatic | Heidelberg Pharma -—D> 187/389 Saroma & MSKCC | ae i Vaccine Program lo <x _——— ‘Pentavalent Vaccine | ‘Ovarian Cancer MSKCC,NCL,GOG | | MSKCC, NANT, NCL Mimte

  7. Slide 7: Antibody Program

    D; Antibody Program liv-h: the

  8. Slide 8: Antibody Discovery Technology Leverages Immune Response

    Antibody Discovery Technology Leverages Immune Response From Many Vac Ca Tye f est Antibody Cloned & Expressed ‘As Monoclonal Mivenvex ivered vat Patients (Rar — ge 7 to 68) Each Patient Immune Best Antibodies Identified a a ONS 5 Sete Genentes Yrs se to Vaccine Patient Receives Fully-Human Best Ant

  9. Slide 9: Validated Antigen Targets Expressed On Solid Tumor Cancers

    Validated Antigen Targets Expressed On Solid Tumor Cancers ry carbohydrate targets —— F502 OO: Sr OOS = Sine pre Sooo Sa og a SS Sep 55 7 SD ODS oe 7 oO oe Discor, 2010 969): p 30828 Mivenvex

  10. Slide 10: Lead Antibody Program Meets Need In Metastatic Colon Cancer

    Lead Antibody P: M . Need In Metastatic i d Colon Cancer attractive molecular target = Increased expression correlated to poor survival! ~ Start Phase I clinical trial in 2015 ‘MabVax’s vaccine alive ‘oan 197 weeks post vaccination) 1 il, Sag AsO, Meal, Immo te atm te 38283), 2 Personal ss 2 commeni

  11. Slide 11: HuMab 5B1 Clinical Candidate Selection

    HuMab 5Bi1 Clinical Candidate Selection S$ ¢# HuMab 5B1-T1: Lead 5B1 v Y Potent cancer cell killing “ , , Y Active as antibody drug conjugate a ; ¢ Zr-HuMab 5B1: Lead 5B1 Program Diagnostic Antibody g : , : Mivenvex

  12. Slide 12: HuMab 5B1-PET Improves Imaging Compared To Standard

    HuMab 5B1-PET Improves Imaging Compared To Standard Agent In Use Today —$—_—_— Journal of Nuclear Medicine pancteatic tumor xenografts (Nov. 2013) Te cae of FCTET sl comp Acie 2 abel SB nods 0750) tomography (CD) il pliar sections of ape of he sane mouse coer ih FOCI ony ht cape ical mer CF esc exer

  13. Slide 13: $1 Billion Market For New Pancreatic And Colon Cancer Treatment

    For New Mi Pancreatic $1 Billion And Colon Cancer Treatment _—— impacts of treatment of pancreatic cancer Significant Number of New 7 Pa _ i Messe "Seiten Potential Patient Population Market Opportunity Relevant patient tease Pancreat nial 16,945 population exceeds 96,000 Taran — now pts per i Colon

  14. Slide 14: MabVax and Juno T-cell Agreement

    Ria 'T J T-cell Agreement MabVax and Juno MSKCC Mivenvex 4

  15. Slide 15: Therapeutic Vaccine Program

    Therapeutic Vaccine Program

  16. Slide 16: Sarcoma Vaccine POC Phase II Results Due 1H2016

    Sarcoma Vaccine POC Phase II Results Due 1H2016 ‘Sarcoma Incidence And Prevalence — 5,290 deaths per year in es snence E68 Up t0 2; Ss suviine Patents new cos Clinical Program Status of 136 patients at 13 sites ly enrolled with all patients fully vaccinated vival — Full = Monitoring for overall sur

  17. Slide 17: Ovarian Vaccine POC Phase II Results Due 1H2016

    Ovarian Vaccine POC Phase II Results Due 1H2016 Prevalence — 13,850 deaths per year in the US. sung Patents new Cases ¢ Clinical Program Status — Fully enrolled and all patients vaccinated = Monitoring for overall survival ¢ Commercial Opportunity non-recombinant components M MabVers

  18. Slide 18: Neuroblastoma Vaccine Program IND 2H2015

    Ni i ine Program IND 2H2015 ¢ Difficult disease = 700 new cases per year US remission — Treatment well tolerated ¢ Transition to Phase 2 Clinical Trial YA in 2014 Orphan Drug status granted by = Single study approval possible = Launch Phase II study 2H2015 (Cl Cans Res 2014:2021375-1382. bled Fray 1

  19. Slide 19: Robust Intellectual Property

    Robust Intellectual Property cancer

  20. Slide 20: Milestones

    Milestones Product HuMab 5B1- Therapeutic HuMab 5B1- PET Imaging HuMabsB1- ADC HuMab 1B7/31F9 Sarcoma Vaccine Program Ovarian Vaccine Program ‘Neuroblastoma ‘Vaccine Program M Mabyens + comple IND ening rocesiogy eso 1 Cope curtains + Opie sod + Couple prin ein 1 oni pasents or ned + GMP mms hetnDan

  21. Slide 21: Discovery Company With Near-Term Milestones

    Di i company With Near- Term Milestone: with significant commercial potential ign Ps therapeutic products (end of 2015) MabVax Therapeutics Holdings, Inc. OTCQB: MBVX Mivenvex

  22. Slide 22: Investment Highlights

    Investment Highlights aa cology secinolnes Substantial ‘Near-Term Clinical Pipeline Efficient Productive Well Managed Mivenvex Capital efficient development model company experience

  23. Slide 23: MabVax Company Contacts

    MabVax therapeutics A Company Company Contacts Gregory Hans Chief Financial Officer [email protected] [email protected] 158-259-9405 x 3 858-259-9405 x 303

  24. Slide 24: Current Capitalization Table

    Current Capitalization Table Miyeover series retered tock vata ess srs pretred stooe sequent vent [art a205- amos [omormecreaoeens ————] Ramon stack nsessis sre pretered tock an vant aiseco series preter sto sdseqvnt event forte 2018" lavas Sans Jsmmonseckat 1500 sure ope recon 2.09 687 pce protecti

MabVax Therapeutics Holdings — Investor Presentation (May 2015) on 6ix